GlassScriptPhysician profile
Elena Shumsky
NPI 1427224237
$8,716.42
in general payments reported to CMS, 2019-2025
29 companies · $1,689 in 2025
The $1,689 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,137 · 2022: $1,745 · 2023: $2,104 · 2024: $2,041 · 2025: $1,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,545 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,544.60 |
| Education | $289.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,144.05 | 2021-2025 | |
| Janssen Biotech, INC. | $822.24 | 2021-2025 | Tremfya |
| Incyte Corporation | $749.91 | 2021-2025 | Opzelura |
| Genzyme Corporation | $712.18 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $697.98 | 2021-2025 | |
| Pfizer INC. | $649.38 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $581.42 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Janssen Scientific Affairs, LLC | $482.98 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $460.55 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $455.91 | 2022-2025 | Sotyktu |
| Amgen INC. | $328.63 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $225.25 | 2021-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $215.09 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $208.81 | 2021-2025 | Siliq, Cabtreo, Jublia |
| Galderma Laboratories, L.P. | $164.30 | 2021-2025 | Nemluvio |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $147.73 | 2025 | Daxi |
| Leo Pharma INC. | $142.72 | 2021-2025 | Adbry |
| Dermavant Sciences, INC. | $124.48 | 2023-2024 | Vtama |
| Genentech USA, INC. | $82.16 | 2021-2023 | Erivedge |
| Ucb, INC. | $66.15 | 2021 | |
| Merck Sharp & Dohme LLC | $63.01 | 2022-2025 | Keytruda |
| Almirall LLC | $52.88 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.19 | 2023 | Spevigo |
| Sanofi-Aventis U.S. LLC | $24.97 | 2021 | |
| Organon LLC | $23.97 | 2025 | |
| Strata Skin Sciences, INC. | $18.93 | 2025 | Xtrac |
| Dermira, INC. | $16.34 | 2021 | |
| Verrica Pharmaceuticals INC. | $14.98 | 2024 | Ycanth |
| Botanix Sb INC | $14.23 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Shumsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.